The National Centre for Nuclear Research POLATOM Radioisotope Centre has received funding from the Medical Research Agency to carry out a non-commercial clinical study in the field of oncology. The research offers new treatment options for one of the most aggressive breast cancers.

Cancer is still one of the leading causes of death worldwide. According to the National Cancer Institute, mortality due to cancer in Poland is more than 15% higher than in the rest of the European Union. Currently, 1,17 million Poles are living with cancer. Every year, 20 000 new cases of breast cancer are diagnosed. Of these, 10-15% are a particularly hard to treat subtype - triple-negative breast cancer (TNBC), characterised by high aggressiveness and rapid growth of tumour cells.

The Medical Research Agency has awarded funding for non-commercial clinical studies and research experiments that aim to improve the situation of cancer patients by developing modern and effective treatments. One of the beneficiaries of the grant is a scientific consortium led by Radioisotope Centre POLATOM with the participation of the Medical University of Łódź and the Medical University of Gdańsk.

The aim of the project is to create a modern diagnostic method that will allow precise treatment adaptations for patients with TNBC. The planned analysis will look at the correlation between initial 99mTc-PSMA-T4 radiolabel uptake and response to neoadjuvant therapy. The data obtained may form the basis for more precise therapeutic protocols for the treatment of TNBC, which may improve the prognosis of patients and increase the efficacy of therapy in the future.